Monday, May 2, 2016 5:30:00 AM PDT | VentureDeal
Westlake Village, California -- Sienna Biopharmaceuticals has received $34 million in its first round of institutional venture capital investment.
Sienna is developing products in aesthetics and dermatology that it believes will improve patient outcomes and physicians' practice of medicine. ARCH Venture Partners led the round, which included Altitude Life Science Ventures, Partner Fund Management and other undisclosed investors. The company did not say how the funding proceeds would be used. CEO Frederick Beddingfield co-founded the firm in January 2016.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
